A Pfizer spokesman told the American Wall Street Journal that the company had to halve its target this year, mainly due to problems in the supply chain. To increase the purchase of raw materials to produce vaccines, they will need much more time than initially planned.
In addition, the results of the clinical phase of vaccine testing were available later than expected, which was helped by the delay, the German reported. Deutsche Wave (DW).
The vaccine is still being decided in the EU
Pfizer vaccine and BioNTecha It is said to be 95% efficient and its general use has so far been approved in the UK and Bahrain.
The European Medicines Agency (EMA), which is responsible for testing medicines and vaccines throughout the European Union (EU), including Slovenia, is conducting an ongoing study against vaccines against them. covidu-19. The review is designed to rapidly assess a potential medication or vaccine in a health crisis, allowing EMI to continuously review data while conducting clinical trials.
The current Pfizer vaccine and BioNTecha, A vaccine from the American pharmaceutical company Moderna, and a vaccine developed by AstraZeneca and Oxford University. Pfizer and. In the application for a conditional marketing authorization BioNTecha The EMA will decide on the permit Modern vaccine on January 12th.
Modern plans to deliver between 100 and 125 million doses of the vaccine in the first quarter of next year. covidu-19, most will go to the US.
